EL&C Baillieu Podcast – CSL Limited (CSL) – Chief Financial Officer David Lamont
CSL is now the largest company listed on the ASX.
The company’s recent interim result was well received by the market, with 11% profit growth on the back of ongoing strong demand for its immunoglobulin (IG) products.
In the latest edition of the EL&C Baillieu Podcast, CSL’s Chief Financial Officer David Lamont discusses:
• COVID-19, including its impact on the business and the assistance CSL is providing in finding a vaccine;
• the ongoing growth of CSL’s plasma business, Behring;
• the turnaround in Seqirus, CSL’s influenza vaccine division; and
• reasons for the company’s upgraded earnings guidance for FY20.
Duration: 19 minutes
Please Listen here